ProKidney (PROK) Earnings Date & Reports

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PROK is expected to report earnings to fall 3.12% to -15 cents per share on May 09

Q1'25

Est.

$-0.16

Q4'24

Missed

by $0.01

Q3'24

Missed

by $0.01

Q2'24

Beat

by $0.09

Q1'24

Beat

by $0.13

The last earnings report on March 17 showed earnings per share of -15 cents, missing the estimate of -15 cents. With 409.08K shares outstanding, the current market capitalization sits at 113.50M.

View a ticker or compare two or three

Compare

PROK